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Abstract
An accurate system for predicting the survival of pa-
tients with oral squamous cell carcinoma (OSCC) will be 
useful for selecting appropriate therapies. A nomogram 
for predicting survival was constructed from 96 patients 
with primary OSCC who underwent surgical resection 
between January 1994 and June 2003 at the Yonsei 
Dental Hospital in Seoul, Korea. We performed uni-
variate and multivariate Cox regression to identify sur-
vival prognostic factors. For the early stage patients 
group, the nomogram was able to predict the 5 and 10 
year survival from OSCC with a concordance index of 
0.72. The total point assigned by the nomogram was a 
significant factor for predicting survival. This nomogram 
was able to accurately predict the survival after treat-
ment of an individual patient with OSCC and may have 
practical utility for deciding adjuvant treatment.
Keywords: c-index, nomogram, oral squamoue cell car-
cinoma, predictive model, survival
Introduction
Oral cancer is the sixth most common cancer in men 
and the twelfth most common cancer in women (Sudbo 
and Reith, 2005). According to statistics from 1999 to 
2002, the annual incidence rate of oral cancer is 5.9% 
in men and 2.2% in women in South Korea (based on 
data from the National Cancer Center in Korea). The ap-
proximately 90% of oral is squamous cell carcinoma 
(Pisani et al., 1999). Patients with oral squamous cell 
carcinoma (OSCC) are often asymptomatic, but may ex-
perience minimal pain in the early stage (Epstein et al., 
2007). Despite the availability of advanced clinical diag-
nostic systems, including computed tomography (CT), 
magnetic resonance imaging (MRI), positron emission 
tomography/computed tomography (PET/CT) imaging 
and improved therapy, the overall 5-year survival rates 
of OSCC over the past two decades are still poor 
(Myoung et al., 2006). Therefore, it is necessary to de-
velop novel prognostic tools for predicting the OSCC 
patients’ status, which could improve survival by allow-
ing enough time for the appropriate therapy to be 
implemented.
  Stephenson et al. (2005) showed that the prediction 
accuracy was improved by the integration of clinical 
variables and gene expression (Stephenson et al., 
2005b). It has already been shown that the expression 
level of specific genes influence survival. Specific pro-
tein expression was used to predict survival in various 
cancers including clear cell renal carcinoma (Kim et al., 
2004). The relationship between p53 and the survival in 
OSCC has been studied by many researchers (Galli et al., 
2009; Goulart et al., 2009; Shah et al., 2009; Smith et 
al., 2009). In these studies, some reported that p53 pre-
dicted the survival of OSCC (Galli et al., 2009; Shah et 
al., 2009) while others did not (Goulart et al., 2009; 
Smith et al., 2009), and Smith et al. (2009) concluded 
that p53 does not predict the progression of OSCC after 
an extensive review of the previous studies. 
  In this study, significant clinical factors for predicting 
survival were identified and a nomogram was con-
structed using these factors. In addition, we evaluated 
the effect of p53 on the survival of OSCC patients, by 
embedding it into the nomogram. The created nomo-
gram was evaluated by c-index.
  Nomogram is a graphical representation of a stat-
istical model and provides the probability of a particular 
clinical outcome, such as death or recurrence (Kattan et 
al., 1998). It has been constructed for predicting survival 
in prostate cancer (Kattan et al., 1999; Stephenson et 
al., 2005a), vulvar cancer (Rouzier et al., 2006), osteo-
sarcoma (Kim et al., 2009), renal cancer (Karakiewicz et 
al., 2007), breast cancer (Rouzier et al., 2005), and ad-
vanced Non-Small-Cell Lung cancer (Hoang et al., 
2005). Furthermore, nomograms have been shown to be 
superior to the traditional staging systems in predicting 
the features of various cancers (Hoang et al., 2005; 
Karakiewicz et al., 2007; Kattan et al., 1999; Kim et al., 
2009; Rouzier et al., 2006; Rouzier et al., 2005; 
Stephenson et al., 2005a). 
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Methods
Patients
We retrospectively investigated 96 patients (71 men and 
25 women) with primary OSCC who underwent surgical 
ablation between January 1994 and June 2003 at the 
Yonsei Dental Hospital in Seoul, Korea.
  The tumor location was the tongue in 26 cases, gingi-
va in 56 cases, and other sites in 14 cases, which in-
cluded the buccal cheek, floor of mouth and lower lip. 
The pathological stage was divided into two groups, 
early and advanced. The I and II stages were grouped 
into the early group, and the III and IV stages were 
grouped into the advanced group. The pathologic 
(pTMN) classification and staging were classified ac-
cording to the 6th edition of AJCC (American Joint 
Committee on Cancer).
Immunohistochemical staining 
Immunohistochemical staining for p53 was performed 
using an EnVision-HRP detection system (Dako, Carpin-
teria, CA, USA). The primary antibody was the p53 
monoclonal antibody, which specifically stained p53 
(Dako). Sections (3μm thick) were cut from tumor tis-
sue blocks mounted on slides and sections were dried 
for 1-2 hours at 56oC. Briefly, sections were deparaffi-
nized in xylene and were rehydrated in graded alcohol. 
After antigen retrieval by the addition of citrate buffer 
(pH, 6.0) with the use of an autoclave at full power for 
4 min, tissue sections were treated with 3% hydrogen 
peroxide for 10 min to block endogenous peroxidase. 
Sections were incubated with p53 (1:50) in a humid 
chamber overnight at 4oC.  
  Slides were then incubated with Envision reagent fol-
lowed by incubation with Diaminobenzidine (DAB) chro-
mogen, slides were counterstained with Mayer’s hema-
toxylin, and then mounted. All of the stained sections 
were imaged by a light microscope.
Immunohistochemical analysis 
Immunohistochemical staining was evaluated by an in-
vestigator who did not know the clinicopathological 
characteristics or the clinical outcome of the patients. 
Specimens were considered positive for staining when 
the tumor cells had dark brown nuclei, and specimens 
were considered negative for staining when the tumor 
cells had only blue nuclei. The percentage of stained tu-
mor cells was graded using a four-point scale (0, ＋1, 
＋2, ＋3, ＋4) as follows: 0, none of the tumor cells 
were stained; ＋1, ≤25% of the tumor cells were 
stained; ＋2, 25% to ≤50% of the tumor cells were 
stained; ＋3, 50% to ≤75% of the tumor cells were 
stained; ＋4, ＞75% of tumor cells were stained. The 
intensity was divided into negative, weak, moderate and 
strong (0, ＋1, ＋2, ＋3). 
Histological grading 
OSCC tissue specimens were subjected to routine hem-
atoxylin and eosin (H & E) staining. Specimens were 
graded into well (G1), moderately (G2) and poorly (G3) 
differentiated squamous cell carcinomas using the World 
Health Organization (WHO) grading system. Thirty-one 
cases were well differentiated, 49 cases were moder-
ately differentiated, and 16 cases were poorly differen-
tiated.
Statistical analysis
The relationships between the clinical factors were test-
ed using the Chi-square statistic. Univariate and multi-
variate analyses were performed to assess the effects of 
various factors on the prediction of survival. The Cox 
proportional hazard model was used to perform the 
multivariate analysis.
  Nomogram for the prediction of survival of OSCC pa-
tients was created with the selected significant variables 
and evaluated by the concordance index (c-index). 
Calibration was assessed by plotting the predicted ver-
sus the actual probability. All statistical analyses were 
performed using R with the Design, eha and Hmisc 
libraries.
Results and Discussion
The clinical features and p53 expression of the 96 pa-
tients used in this study are summarized in Table 1. 
They underwent surgical resection between January 
1994 and June 2003 at the Severance Hospital in Seoul, 
Korea. The association of clinical factors and patho-
logical groups was shown using p-values from 
chi-square test in Table 1. 
  Tumor site, LN metastasis and T stage were sig-
nificantly and differentially distributed between the early 
and advanced groups. The outcome pattern was also 
significantly different. This result indicated that early and 
advanced groups have different clinical characteristics; 
therefore, the predictive model should be identified for 
each stratified groups. In regards to tumor sites, 32.5% 
of gingiva was in the early stage while 77% was in the 
advanced group. Lymph node metastasis was not ob-
served in the early group while over 60% was in the ad-
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Table 1. Characteristics of patients with OSCC (N=96)
Clinical variables Patients(n=96)
Early stage 
(n=40)
Advanced stage 
(n=56)
p-value 
(Early vs. Advanced)
Age
  ＜60
  ≥60
Sex
　Female
　Male
LN metastasis (n=73)
　N (−)
　N (＋)
Tumor site
　Gingiva
　Tongue
　Other
Histopathologic grade 
　G1
　G2
　G3
Distant metastasis 
　No 
　Yes
Pathologic stage (P stage)
　Early
　Advanced
T stage
　T1
　T2
　T3
　T4
p53
　−＋
　＋＋ ＋＋＋
Disease outcome 
　Survived
　Dead
42 (56%)
54 (44%)
25 (26%)
71 (74%)
62 (65%)
34 (35%)
56 (58%)
26 (27%)
14 (25%)
31 (32%)
49 (51%)
16 (17%)
89 (92%)
 7 (8%)
40 (42%)
56 (58%)
19 (20%)
33 (34%)
23 (24%)
21 (22%)
37 (39%)
59 (61%)
45 (47%)
51 (53%)
16 (40%)
24 (60%)
 9 (22.5%)
31 (77.5%)
40 (100%)
 0 (0%)
13 (32,5%)
18 (40%)
 9 (22.5%)
13 (32.5%)
22 (55%)
 5 (12.5%)
37 (92.5%)
 3 (7.5%)
40 (100%)
 0 (0%)
16 (40%)
24 (60%)
 0 (0%)
 0 (0%)
26 (60%)
14 (40%)
24 (60%)
16 (40%)
26 (46%)
30 (54%)
16 (29%)
40 (71%)
22 (39%)
34 (61%)
43 (77%)
 8 (14%)
 5 (9%)
18 (32%)
27 (48%)
11 (20%)
52 (93%)
 4 (7%)
 0 (0%)
56 (100%)
 3 (5.5%)
 9 (16%)
23 (41%)
21 (37.5%)
32 (57%)
24 (43%)
21 (37.5%)
35 (62.5%)
0.6764
0.6654
3.304e-09
7.793e-05
0.6295
0.74
NA
1.127e-12
0.3755
0.04878
vanced group.
  The primary end point was survival time. The free-sur-
vival interval was defined as the time between the date 
of surgery to the last visit or the date when the patient 
died. Univariate and multivariate analyses were carried 
out to identify the characteristics associated with 
survival. Table 2 shows the results of the univariate and 
multivariate Cox regression analysis for the whole 
dataset. 
  P stage and LN metastasis were significant factors in 
the univariate analysis and no significant factors were 
identified in the multivariate analysis. Therefore, it would 
be desirable to construct a predictive model separately 
using the P stage. It would also be possible to con-
struct separate models using LN metastasis, because 
LN metastasis was shown to be a significant factor in 
the univariate analysis.
  To explore the association of p53 expression with 
other clinical factors, a chi-square test was performed. 
The results were summarized in Table 3. 
  From Table 3, p53 was shown to not be significantly 
associated with any clinical factors in the whole dataset 
and advanced group, and it was only significantly asso-
ciated with the Tumor Site in the early group. These re-
sults indicated that p53 can be a novel and independent 
predictor in the prediction model. In the separate analy-
sis of the early and advanced groups, LN metastasis 
had only one category, ‘negative’, in the early group; 
therefore, we excluded this variable from the model 
(Table 4). 
  No significant factors were identified in the advanced 
group. However, Grade was significant and p53 was 
shown to be slightly significant in the early group, even 
though the p-value was only marginally larger than 0.05. 
Therefore, we constructed a nomogram for the early 
stage of OSCC.
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Table 2. Univariate and multivariate analysis using the whole dataset (n=96) 
Variables
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
LN metastasis
  −：＋  
Histopathologic Grade 
  G1：G2
  G3：G2
Distant Metastasis 
  N：Y
P stage
  early：advanced
Tumor site
  Tongue：gingiva
  Other：gingiva
T stage
  T1：T2
  T3：T2
  T4：T2
p53
  −＋:＋＋ ＋＋＋
1.90 (1.10, 3.3)
0.84 (0.44, 1.59)
1.23 (0.58, 2.60)
0.44 (0.11, 1.80)
0.54 (0.3, 0.98)
0.72 (0.36, 1.44)
1.14 (0.54, 2.40)
0.62 (0.25, 1.57)
1.09 (0.53, 2.25)
1.77 (0.88, 3.56)
1.26 (0.73, 2.20)
0.0225
0.591
0.350
0.250
0.044
0.359
0.732
0.3147
0.2655
0.1333
0.409
1.27 (0.50, 3.20)
0.82 (0.41, 1.64)
1.66 (0.74, 3.74)
0.32 (0.07, 1.57)
0.89 (0.20, 3.26)
1.09 (0.47, 2.53)
1.99 (0.79, 5.03)
0.66 (0.25, 1.74)
1.53 (0.48, 4.88)
2.08 (0.73, 5.89)
1.58 (0.84, 2.99)
0.619
0.566
0.133
0.160
0.861
0.837
0.145
0.401
0.243
0.098
0.150
Table 3. Relationship between p53 & clinical characteristics
Variables
p53 p-value
−  ＋ (n=37) ＋＋  ＋＋＋ (n=59) Whole data set (n=96) Early (n=40) Advanced (n=56)
LN matastasus (N=73)
　n (−)
　n (＋)
Tumor site
　Gingiva
　Tongue
　Other
Histopathologic grade
　G1
　G2
　G3
Distant metastasis 
　No
　Yes
P stage
　Early
　Advanced
T stage
　T1
　T2
　T3
　T4
27 (73%)
10 (27%)
23 (62%)
10 (27%)
 4 (11%)
15 (41%)
17 (46%)
 5 (13%)
35 (95%)
2 (5%)
18 (49%)
19 (51%)
 7 (19%)
15 (41%)
 9 (24%)
 6 (16%)
35 (59%)
24 (41%)
33 (56%)
16 (27%)
10 (17%)
16 (27%)
32 (54%)
11 (19%)
54 (92%)
5 (8%)
19 (32%)
37 (68%)
12 (20%)
18 (31%)
14 (24%)
15 (25%)
0.2535
0.6911
0.3802
0.8732
0.3755
0.6654
NA
0.01633
0.1794
0.3051
NA
0.8457
0.5495
0.4086
0.4652
0.8756
NA
0.4697
  A nomogram predicting the 5-year and 10-year surviv-
al with clinical factors and p53 expression was con-
structed for the early group (Fig. 1). Metastasis was ex-
cluded from the model identification because it was 
highly unbalanced between the two categories (Y and 
N). 
  The C-index was 0.72 in the nomogram for the early 
group and p53 was not an influential factor in prediction 
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Table 4. Multivariate Cox regression for early stage (n=40) and advanced stage (n=56)
Variables
Early stage Advanced stage
HR (95% CI) p HR (95% CI) p
LN metastasis
  −：＋
Histopathologic grade
　G1：G2
　G3：G2
Distant merastasis 
　Y：N
Tumor site
　Tongue：gingiva
　Other：gingiva
T stage
　T1：T2
　T1：T3
　T2：T3
　T4：T3
p53
　−＋ : ＋＋ ＋＋＋
NA
0.24 (0.06, 0.94) 
 6.56 (1.22, 35.40) 
0.51 (0.05, 5.52)
1.20 (0.33, 4.33)
 3.32 (0.76, 14.59)
0.41 (0.11, 1.54)
2.66 (0.87, 8.11)
NA
0.0392
0.0016
0.57808
0.7825
0.1589
0.18639
0.08570
0.55 (0.21, 1.42)
1.72 (0.73, 4.03)
1.37 (0.50, 3.71)
0.38 (0.05, 3.14)
 1.30 (0.42, 4.08)
3.26 (0.87, 12.21)
0.24 (0.03, 1.87) 
0.66 (0.19, 2.29) 
1.44 (0.57, 3.65) 
1.30 (0.59, 2.85)
0.2139
0.2135
0.6838
0.3694
0.6486
0.0797
0.3005
0.1721
0.0805
0.5174
Fig. 1. Nomogram for predicting the 
5-year and 10-year survival after surgery 
on OSCC patients.
even though it was slightly significant in the multivariate 
analysis. The nomogram operates by summing the 
points of each independent covariate. The probabilities 
of 5-year and 10-year survival are identified by the cal-
culated total point (Fig. 2).
  Fig. 2 shows that the probability of free-survival in-
creased as the total points increased. For example, if 
the total point was 140 for a patient, the probabilities of 
5 and 10 year survival would be 90% and 78%, 
respectively. We also investigated if the total point cal-
culated by the nomogram would be a novel predictor. 
The mean of total points assigned by the nomogram 
was 116.5 and we stratified patients into two groups us-
ing this value. The sample size for the early stage was 
40, which was not sufficient to identify subsets; how-
ever, we examined if the total points derived from the 
nomogram could significantly classify the survival of 
OSCC. For this, the Kaplan-Meier survival curve was 
plotted and the Log-Rank test was performed (Fig. 3).
  Fig. 3 shows the stratification of the survival curves 
based on total points assigned by the nomogram, and 
those curves were significantly different (p-value＜0.05). 
This p-value should be considered as a measure of 
curve separation. Based on the results shown in Figure 
3, the total point calculated by nomogram could be a 
combined marker for predicting survival.
  The nomogram can be a model in which known prog-
nostic factors can be combined and used for risk pre-
diction in cancer (Bianco, 2006). One advantage of 
nomograms is that they are weighted models comprised 
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Fig. 2. The relationship between the total 
point derived from the nomogram and the 
probabilities of 5-year and 10-year survival.
Fig. 3. Kaplan-Meier survival curves based on stratification
using the total points assigned by the nomogram. The 
p-value comparing curves using Log rank test was less 
than 0.05 (Chi-square statistic was 3.9).
of independent prognostic factors, which provide an ap-
preciation of the magnitude of impacts of individual fac-
tors on outcome probability (Kim et al., 2009). An accu-
rate survival prediction model would be useful for pa-
tient counseling, planning follow-up, and selecting pa-
tients for additional treatment (Kim et al., 2004).
  The data set that was used in this study had sig-
nificantly different characteristics between early and ad-
vanced stages. In this case, identification of the predict-
able model for each stratified groups could be more 
reliable. In addition, no significant factors were detected 
in the advanced group when we performed multivariate 
analysis for each groups. Therefore, we developed and 
validated a nomogram for predicting 5-year and 10-year 
survival probability of OSCC patients in the early stage 
that underwent surgical resection. The nomogram pre-
dicts the probability of survival with a concordance in-
dex of 0.72. 
  In this study, grade was found to be a key prognostic 
factor in the early stage group, while it was not sig-
nificant in the advanced group. p53 was slightly sig-
nificant in the early stage (p=0.0857), which was pre-
viously shown not to be able to predict the progression 
of OSCC (Smith et al., 2009). However, we included p53 
in the predictive model when constructing the nomo-
gram, and explored the influence of p53. In this analy-
sis, p53 was shown to be significant in the nomogram, 
and its high expression was correlated with the in-
creased probability of survival even though it did not 
improve the c-index. 
  To evaluate the constructed nomogram, we de-
termined whether the total points calculated by the 
nomogram could be used as a predictive factor, besides 
the c-index. The mean value of the total points was 
116.5, and we divided patients into two groups using 
this value. A new marker based on the total points was 
determined to be a significant factor in the survival 
model (p＜0.05). Therefore, a factor based on the total 
points can be a novel predictive marker. In addition, the 
randomization of patients in clinical trials by composite 
risk factors specific to OSCC would be possible using 
the nomogram. 
  This nomogram would be a useful tool for physicians 
who have to make decisions in the diagnosis of OSCC 
patients. For example, a patient with high expression of 
p53, G2 and T2 stage squamous cell carcinoma of the 
oral tongue is predicted to have a 79.8% and 60.7% 
probability of 5-year and 10-year survival, respectively. 
If the physicians can accurately estimate the probability 
of survival, they could be able to improve the life of pa-
tients by choosing more appropriate treatment.
  In this study, we constructed a predictive nomogram 
for the early stage of OSCC, based on a sample size 
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of 40. This sample size may not be large enough to 
construct a predictive model. In addition, there might be 
more variables that we did not include in the model. 
However, this is the first prognostic nomogram devel-
oped to predict the survival of Korean patients. The 
constructed nomogram could be improved with more 
data and by including biological candidates in the pre-
dictive model. 
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